2024年中国帕金森病药物治疗行业概览：患病负担全球占比36.5%，治疗方案由多巴胺替代转向精准诊疗前景如何？

Investment Rating - The report does not explicitly state an investment rating for the Parkinson's disease medication industry in China Core Insights - The burden of Parkinson's disease in China accounts for approximately 36.5% of the global patient population, indicating a significant demand for innovative treatment solutions [6][51] - The shift from dopamine replacement therapy to personalized and precise treatment plans is becoming a focal point for pharmaceutical companies and research institutions [6][8] - The increasing prevalence of Parkinson's disease among the aging population in China is driving the need for tailored medication regimens that address both motor and non-motor symptoms [6][8] Summary by Sections Industry Overview - Parkinson's disease is characterized by a reduction in dopamine in the striatum and abnormal protein aggregation, leading to various motor and non-motor symptoms [6][12] - The treatment landscape includes dopamine receptor agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergic drugs, with a focus on personalized treatment plans [6][12][15] Development History - The industry has evolved from initial explorations in the 19th century to the establishment of dopamine replacement therapy as a primary treatment method in the early 21st century [18][19][20] - Recent years have seen a shift towards domestic drug development, reducing reliance on imported medications [8][18] Policy Overview - Recent policies emphasize the importance of addressing the healthcare needs of the aging population, optimizing medical resources, and enhancing the accessibility of Parkinson's disease treatments [24][25] - The government is promoting research and development in the field, which is expected to accelerate the introduction of new therapies [24][25] Market Size and Growth - The market for Parkinson's disease medications in China is projected to exceed 5 billion yuan by 2028, driven by the increasing patient population and the complexity of treatment needs [47][51] - The market for early-stage patients is expected to grow steadily, while the market for mid-to-late-stage patients, who often require more complex treatment regimens, is anticipated to be the primary growth driver [49][51] Patient Demographics and Treatment Pathways - A significant portion of Parkinson's patients also experience multiple comorbidities, highlighting the need for individualized treatment plans that address both primary and secondary symptoms [40][43] - The trend of younger patients being diagnosed with Parkinson's disease is increasing, which may lead to a rise in online medication sales as younger patients are more familiar with digital purchasing [40][43]